BioPhenyx is the first company in the world that quantitatively determines how genetic sequence variants (“what is coded?”) impact cell phenotypes (“what happens?”)
DNA is the code of life and disease. Despite recent developments, there are still significant gaps in our understanding of how genetic sequence variants (aka mutations) or entire genes affect the cellular functions known as “phenotype,” which simply refers to an observable trait.
With its proprietary CRISPR-Select technology, BioPhenyx is the first company in the world that quantitatively determines how genetic sequence variants (“what is coded?”) impact cell phenotypes (“what happens?”). BioPhenyx introduces mutation of interest in any desired cell type and determines the effects, in absence or presence of drugs, as desired. Importantly, quantitative results are achieved in a cell culture within weeks without the need for cell line generation and clonal selection.
BioPhenyx was established to commercialize the CRISPR-Select technology, developed at University of Copenhagen: University of Copenhagen – University of Copenhagen (ku.dk).
Development of CRISPR-Select lean on years of research and translational activities at the Biotech Research and Innovation Center: BRIC – University of Copenhagen (ku.dk).
BRIC is the origin and first home of important Danish companies and technology developments, as exemplified by EpiTherapeutics (later acquired by Gilead Sciences: Gilead Sciences Acquires EpiTherapeutics).
At BRIC new approaches to tackle precision medicine challenges were needed; in highly specific details we needed to answer the following questions: – which genes and gene variants cause e.g., familial breast and ovarian cancer? Precision medicine experts and CRISPR-editing experts teamed up to solve this major problem, which resulted in the patented CRISPR-Select technology. The work was led by Claus Storgaard Sørensen Sørensen Group – University of Copenhagen (ku.dk) and Morten Frödin Frödin Group – University of Copenhagen (ku.dk).
BioPhenyx now offers CRISPR-Select analyses on a fee-for service basis for use in basically any disease.
BioPhenyx offers CRISPR-Select on a small or grand scale, across cells from all major organisms, all genes (including essential genes) and all small mutations (point mutations/SNVs, substitution of amino acid(s), stop mutations, frameshift mutations, indel mutations, splice site mutations).
BioPhenyx thereby provides a missing link to precision medicine approaches that often fail with other methods, because the current general understanding of the genetic background for a given disease lacks depth and precision.
BioPhenyx offers CRISPR-Select based services to leading corporations in the Pharma/Biotech industry, as well as use of CRISPR-Select as a basis for development of novel groundbreaking solutions.